Cargando…
Interleukin-6 gene-174 G/C promoter polymorphism is not associated with multiple myeloma susceptibility: evidence from meta-analysis: A systematic review and meta-analysis
PURPOSE: Presently, whether interleukin-6 (IL-6) gene-174 G/C promoter polymorphism is correlated to the susceptibility of multiple myeloma (MM) remains controversial. For this reason, the method of meta-analysis was applied to exploring the association between IL-6 gene-174 G/C promoter polymorphis...
Autores principales: | Dong, Xiaohui, Zhang, Zongxin, Shou, Lihong, Shen, Jingjing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545425/ https://www.ncbi.nlm.nih.gov/pubmed/33578591 http://dx.doi.org/10.1097/MD.0000000000024647 |
Ejemplares similares
-
Association between the interleukin-6 genetic polymorphism 174 G/C and thrombosis disorder risk: Meta-analysis of 10,549 cases and 19,316 controls
por: Ren, Honggang, et al.
Publicado: (2016) -
MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis
por: Xu, Peipei, et al.
Publicado: (2019) -
Huanglian Jiedu Decoction for treatment of multiple myeloma: A protocol for a systematic review and meta-analysis
por: An, Na, et al.
Publicado: (2020) -
Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials
por: Huang, Zeng-Yi, et al.
Publicado: (2023) -
Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies
por: Zhu, Wanqiu, et al.
Publicado: (2016)